论文部分内容阅读
目的:观察糖肾Ⅰ号方联合缬沙坦治疗糖尿病肾病的临床疗效。方法:将81例糖尿病肾病患者随机分为对照组和治疗组,在内科常规抗糖尿病治疗的基础上,对照组40例给予缬沙坦胶囊口服,治疗组41例在对照组治疗基础上加用糖肾Ⅰ号方治疗。以15天为1疗程,2组均治疗3疗程,比较2组的临床疗效,并观察治疗前后空腹血糖(FBG)、早餐后2 h血糖(P2h BG)、糖化血红蛋白(Hb A1c)、尿白蛋白排泄率(UAER)、尿微量白蛋白(U-m Alb)、血肌酐(SCr)、尿素氮(BUN)的变化。结果:对照组总有效率为67.5%,治疗组总有效率为82.9%,2组比较,差异有统计意义(P<0.05)。治疗后,2组FBG、P2h BG、Hb A1c水平与治疗前比较无明显变化,差异均无统计学意义(P>0.05)。治疗组UAER、U-m Alb、BUN和对照组UAER、U-m Alb与治疗前比较,差异均有统计学意义(P<0.01,P<0.05);治疗组UAER、BUN、U-m Alb的改善程度均优于对照组(P<0.01,P<0.05)。结论:糖肾Ⅰ号方联合缬沙坦胶囊治疗糖尿病肾病较单用缬沙坦疗效更为确切,可有效缓解糖尿病肾病患者的临床症状,改善肾功能。
Objective: To observe the clinical efficacy of Tangshen I and Valsartan in the treatment of diabetic nephropathy. Methods: Eighty-one patients with diabetic nephropathy were randomly divided into control group and treatment group. On the basis of conventional anti-diabetic treatment, 40 patients in control group were given valsartan capsules orally, while 41 patients in treatment group were treated with control group Sugar Kidney No. I treatment. The course of treatment was 15 days. The two groups were treated for 3 courses. The clinical curative effect was compared between the two groups. The levels of fasting blood glucose (FBG), 2h postprandial blood glucose (Hb A1c), urinary white UAER, Um Alb, SCr and BUN were measured. Results: The total effective rate of the control group was 67.5%, and the total effective rate of the treatment group was 82.9%. There was significant difference between the two groups (P <0.05). After treatment, there was no significant difference in FBG, P2h BG and Hb A1c between the two groups (P> 0.05). UAER, Um Alb and BUN in the treatment group and UAER and Um Alb in the control group were significantly different from those before treatment (P <0.01, P <0.05). The improvement of UAER, BUN and Um Alb in the treatment group was better than that in the control group Control group (P <0.01, P <0.05). Conclusion: Tangshen Ⅰ and Valsartan capsules can treat diabetic nephropathy more effectively than valsartan alone, which can effectively relieve the clinical symptoms and improve renal function in patients with diabetic nephropathy.